Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 6/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.46 |
| ▸ | CCR9 | P51686 | 5/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001949 | 0.89 | CCR2 (0.55) | CCR2ABCB11CCR9GPR35 | |
| SCHEMBL2994597 | 0.89 | CCR2 (0.41) | CCR2ABCB11CCR9GPR35 | |
| SCHEMBL2995558 | 0.88 | CCR2 (0.56) | CCR2ABCB11CCR9GPR35 | |
| SCHEMBL2999654 | 0.87 | F10 (0.45) | CCR2ABCB11GPR35CNR1 | |
| SCHEMBL4384057 | 0.85 | CCR2 (0.58) | CCR2ABCB11CCR9GPR35 | |
| SCHEMBL3119623 | 0.82 | CCR2 (0.55) | CCR2ABCB11CCR9GPR35CNR2 | |
| SCHEMBL3005519 | 0.82 | CCR2 (0.60) | CCR2ABCB11CCR9GPR35 | |
| SCHEMBL3001509 | 0.81 | L3MBTL1 (0.42) | CCR2GPR35CNR1 | |
| SCHEMBL297540 | 0.80 | CCR2 (0.46) | CCR2ABCB11CCR9GPR35 | |
| SCHEMBL3002097 | 0.78 | CCR2 (0.57) | CCR2ABCB11CCR9GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| CN-101563337-A | Indole compounds | MICROBIA INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2049520-A2 | INDOLE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008019357-A2 | INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | CCR2 107/4885ABCB11 3804/4885CCR9 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.